logo

For the Inventor, By the Inventor

Toyama, Japan

Shohachi Murakami

USPTO Granted Patents = 12

Average Co-Inventor Count = 10.3

ph-index = 3

Forward Citations = 29(Granted Patents)


Company Filing History:

goldMedal12 out of 159 
 
Toyama Chemical Co., Ltd.
 patents

Years Active: 1983-1988

Loading Chart...
12 patents (USPTO):Explore Patents
1. 4744985 - Novel substances having carcinostatic and immunostimulating activity, (1988-05-17),
2. 4591558 - Novel substances having antitumor and immunostimulating activity, (1986-05-27),
3. 4547462 - Process for preparing substance having carcinostatic and (1985-10-15),
4. 4477666 - 1-(4-Aminobenzyl)-2,3-dioxopiperazine derivatives, acid addition salts (1984-10-16),
5. 4477664 - Novel 1-(4-piperidiniobenzyl)-2,3-dioxopiperazine derivatives or acid (1984-10-16),
6. 4477437 - Substances having carcinostatic and immunostimulating activity (1984-10-16),
7. 4460774 - 1-(4-Aminobenzyl)-2,3-dioxopiperazine derivatives, acid addition salts (1984-07-17),
8. 4459407 - 1-(4-Aminobenzyl)-2,3-dioxopiperazine derivatives and salts thereof (1984-07-10),
9. 4448963 - 4-[4-(Thiazolyl-amino)benzyl]-2,3-dioxopiperazine derivatives, acid (1984-05-15),
10. 4444753 - Pharmaceutical composition comprising extract from poison pouch contents (1984-04-24),
11. 4436921 - 1-(4-Aminobenzyl)-2,3-dioxopiperazine derivatives, acid addition salts (1984-03-13),
12. 4370316 - Pharmaceutical composition comprising extract from poison pouch contents (1983-01-25),

Title: **Shohachi Murakami: Innovator in Cancer Treatment**

Introduction

Shohachi Murakami is a notable inventor based in Toyama, Japan, recognized for his significant contributions to medical innovations. With a portfolio of 12 patents, he has focused on developing novel substances for cancer treatment, pushing the boundaries of therapeutic science.

Latest Patents

Murakami's recent patents demonstrate his commitment to creating impactful solutions in the field of oncology. His first patent, titled "Novel substances having carcinostatic and immunostimulating activity," describes substances derived from cultures of Fusobacterium bacteria. These compounds show promise for treating cancerous diseases in lower warm-blooded animals. The focus of this disclosure is on the substances themselves, the preparation processes, and the carcinostatic agents containing them.

Another significant invention, "Novel substances having antitumor and immunostimulating activity," presents TF-2 substances also derived from Fusobacterium cultures. This innovative discovery has the potential to treat cancerous diseases in various mammals, including humans. The patent outlines the substances, their preparation, and the antitumor agents containing them, showcasing Murakami's dedication to advancing cancer therapies.

Career Highlights

Throughout his career, Shohachi Murakami has made strides in pharmaceutical science working at Toyama Chemical Co., Ltd. His pioneering work in developing novel treatments has not only garnered numerous patents but has also contributed significantly to the scientific community's understanding of immunostimulatory and carcinostatic substances.

Collaborations

Collaborating with esteemed colleagues such as Isamu Saikawa and Hisatsugu Tsuda, Murakami has forged partnerships that drive innovation and streamline research efforts within the company. These collaborations underscore the importance of teamwork in the quest for groundbreaking discoveries in cancer therapeutics.

Conclusion

In summary, Shohachi Murakami stands out as a remarkable inventor whose innovations hold promise for the future of cancer treatment. With his extensive patent portfolio and collaborative spirit, he continues to pave the way for advancements that could redefine therapeutic approaches to cancer care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…